$HURA News

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

HURA: Refining TBS-2025 Development Plan

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Citizens Initiates Coverage On TuHURA Biosciences with Market Outperform Rating, Announces Price Target of $9

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses

Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

HURA: 2025 Financial Results

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation

TuHURA Biosciences Files $50M At-The-Market Common Stock Offering With H.C. Wainwright As Sales Agent

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TuHURA Biosciences Regains Nasdaq Compliance